2026 年第 4 期 第 21 卷

血脂康对心血管疾病的多靶点作用机制与临床证据研究现状

Research status of the multi-target mechanism and clinical evidence of Xuezhikang in cardiovascular diseases

作者：罗涵中1刘立波1张耘启1安子玉1张欢1张丽君2田晋帆1宋现涛3

英文作者：Luo Hanzhong1 Liu Libo1 Zhang Yunqi1 An Ziyu1 Zhang Huan1 Zhang Lijun2 Tian Jinfan1 Song Xiantao3

单位：1首都医科大学附属北京安贞医院心内科，北京100029；2首都医科大学附属北京安贞医院放射科，北京100029；3首都医科大学附属北京友谊医院心内科，北京100050

英文单位：1Department of Cardiology Beijing Anzhen Hospital Capital Medical University Beijing 100029 China; 2Department of Radiology Beijing Anzhen Hospital Capital Medical University Beijing 100029 China; 3Department of Cardiology Beijing Friendship Hospital Capital Medical University Beijing 100050 China

关键词：心血管疾病；血脂康；脂质代谢；炎症；临床应用

英文关键词：Cardiovasculardiseases;Xuezhikang;Lipidmetabolism;Inflammation;Clinicalapplication

• 摘要：

• 血脂康来源于红曲米，含有13种天然他汀类物质（无结晶的洛伐他汀及同类物质）和多种生物活性成分。其通过抑制3-羟基-3-甲基戊二酰辅酶A还原酶并激活过氧化物酶体增殖物激活受体相关信号通路，协同调节血脂谱和胆固醇代谢；同时通过抑制核因子κB活化并促进核因子E2相关因子2的核转位，在心血管疾病治疗中发挥抗炎、抗氧化及血管内皮保护等作用。临床研究与实践均表明血脂康可显著降低患者低密度脂蛋白胆固醇及甘油三酯水平，并减轻炎症状态，抗氧化。在合并糖尿病、心肌梗死病史等心血管高危人群中有助于降低心血管事件发生风险并改善预后。作为单药治疗，其调脂效果确切；亦可与他汀类药物或非他汀类降脂药物（如依折麦布、前蛋白转化酶枯草溶菌素9抑制剂）联合应用协同调脂，治疗心血管疾病。基于血脂康总体耐受性良好和多靶点作用特性，血脂康为心血管疾病的一级和二级预防提供了具有临床价值的治疗选择。

• Xuezhikang is derived from red yeast rice and contains 13 natural statins (including non-crystalline lovastatin and its analogs) as well as a variety of bioactive components. It synergistically regulates the lipid profile and cholesterol metabolism by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and activating peroxisome proliferator-activated receptor-related signaling pathways. Meanwhile, it exerts anti-inflammatory, antioxidant and vascular endothelial protective effects in the treatment of cardiovascular diseases by inhibiting nuclear factor-κB activation and promoting the nuclear translocation of nuclear factor E2-related factor 2. Both clinical studies and practice have shown that Xuezhikang can significantly reduce the levels of low-density lipoprotein cholesterol and triglycerides in patients, and alleviate inflammatory status and oxidative stress. It helps to reduce the risk of cardiovascular events and improve prognosis in high-risk cardiovascular populations with a history of diabetes, myocardial infarction and other comorbidities. As a monotherapy, it has a definite lipid-lowering effect; it can also be combined with statins or non-statin lipid-lowering drugs (such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors) for synergistic lipid-lowering in the treatment of cardiovascular diseases. Based on its good overall tolerability and multi-target action characteristics, Xuezhikang provides a clinically valuable therapeutic option for the primary and secondary prevention of cardiovascular diseases.